US Patent

US11179367 — Pharmaceutical compositions for treating cystic fibrosis

Method of Use · Assigned to Vertex Pharmaceuticals Inc · Expires 2037-12-08 · 12y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of treating cystic fibrosis by administering a pharmaceutical composition.

USPTO Abstract

A pharmaceutical composition comprising Compound I:Methods of treating cystic fibrosis comprising administering one or more of such pharmaceutical compositions to a patient.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3253 —
U-3597 —
U-3597 —
U-3253 —

Patent Metadata

Patent number
US11179367
Jurisdiction
US
Classification
Method of Use
Expires
2037-12-08
Drug substance claim
No
Drug product claim
Yes
Assignee
Vertex Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.